The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Clarity about the superiority of the two trastuzumab-containing ADCs in HER2 ... and Roche Products Ltd. Co-authors reported multiple relationships with industry.

and AZ/Daiichi Sankyo's Enhertu (trastuzumab deruxtecan). That is down to the company's ADC technology platform, which means that the cytotoxic payload that circulates systemically after ...

The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients with HER2-low or HER2-ultraow metastatic disease that progressed after endocrine therapy.

The addition of 64/67Cu-SAR-trastuzumab complements Clarity’s broader pipeline, which includes SAR-Bombesin, SARTATE, and SAR-bisPSMA. The company plans to conduct a Phase 1/2a theranostic study to ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

and co-authors performed a meta-analysis of mitochondria-related gene expression data in trastuzumab-treated cardiomyocytes. They analyzed 1,243 genes and observed 69 up-regulated genes after ...

The news: Clarity Pharmaceuticals shares tumbled after it announced a new treatment in its pipeline for breast cancer. The numbers: The clinical-stage radiopharmaceutical company’s shares dropped 5.36 ...

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...